Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Byrne, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Byrne, P. M.
The Proceedings of the American Thoracic Society 1:105-108 (2004)
© 2004 The American Thoracic Society

Pharmacologic Interventions to Reduce the Risk of Asthma Exacerbations

Paul M. O'Byrne

Firestone Institute for Respiratory Health, St. Joseph's Hospital, Hamilton, Ontario, Canada

Correspondence and requests for reprints should be addressed to Paul M. O'Byrne, M.B., F.R.C.P.I., F.R.C.P.C., Firestone Institute for Respiratory Health, St. Joseph's Hospital, 50 Charlton Avenue East, Hamilton, ON, L8N 4A6 Canada. E-mail: obyrnep{at}mcmaster.ca

Inhaled corticosteroids (ICS) are known to reduce the risk of asthma exacerbations and asthma fatalities. In addition, an increased dose of ICS at the onset of exacerbation can reduce the need for systemic corticosteroids, although this may require a fourfold increase in dose. The overuse of short-acting ß2-agonists or long-acting inhaled ß2-agonists, used as monotherapy, increases these risks. By contrast, the use of long-acting ß2-agonists together with ICS has been demonstrated to reduce the doses of ICS needed for ideal asthma control, as well as to reduce asthma exacerbations. This has been best demonstrated in the Formoterol and Corticosteroids Establishing Therapy and Oxis and Pulmicort Turbuhaler in the Management of Asthma studies, which demonstrated that the combination of inhaled budesonide and formoterol reduced the risk of asthma exacerbations over that achieved by budesonide alone. Even the "as needed" use of inhaled formoterol added to ICS reduces asthma exacerbations. The combination inhaler, Symbicort, containing both budesonide and formoterol, reduced the risk of asthma exacerbations to a similar extent as the monocomponents, given separately. Treatment with either leukotriene receptor antagonists or anti-IgE also reduces the risks of asthma exacerbations, but the magnitude of the benefit compared with the combination of ICS and long-acting ß2-agonists is not yet known.

Key Words: asthma • exacerbation • inhaled corticosteroids • long-acting inhaled ß2-agonists




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
J. G. Teeter and R. J. Riese
Dissociation of Lung Function Changes with Humoral Immunity during Inhaled Human Insulin Therapy
Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1194 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. P. Galant, T. Morphew, S. Amaro, and O. Liao
Current Asthma Guidelines May Not Identify Young Children Who Have Experienced Significant Morbidity
Pediatrics, April 1, 2006; 117(4): 1038 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. Buhl and S. G. Farmer
Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma
Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Thoracic Society. 		 
Tobacco